The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Cancer nanomedicines: So many papers and so few drugs!
Open accessAbstract
This review identifies a timeline to nanomedicine anticancer drug approval using the business model of inventors, innovators and imitators. By evaluating the publication record of nanomedicine cancer therapeutics we identified a trend of very few publications prior to FDA approval. We first enumerated the publications related to cancer involving polymers, liposomes or monoclonal antibodies and determined the number of citations per publication as well as the number of published clinical trials amongst the publications. Combining these data with the development of specific nanomedicines, we are able to identify an invention phase consisting of seminal papers in basic science necessary for the development of a specific nanomedicine. The innovation phase includes the first report, the development and the clinical trials involving that nanomedicine. Finally, the imitation phase begins after approval when others ride the wave of success by using the same formulation for new drugs or using the same drug to validate other nanomedicines. We then focused our analysis on nanomedicines containing camptothecin derivatives, which are not yet approved including two polymers considered innovations and one liposomal formulation in the imitation phase. The conclusion that may be drawn from the analysis of the camptothecins is that approved drugs reformulated in polymeric and liposomal cancer nanomedicines have a more difficult time navigating through the approval process than the parent molecule. This is probably due to the fact that for most currently approved drugs, reformulating them in a nanocarrier provides a small increase in performance that large pharmaceutical companies do not consider being worth the time, effort and expense of development. It also appears that drug carriers have a more difficult path through the clinic than monoclonal antibodies. The added complexity of nanocarriers also deters their use to deliver new molecular entities. Thus, the new drug candidates that might be most improved by drug delivery in nanocarriers are not formulated in this fashion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Bangham, A. D., & Horne, R. W. (1964) · Journal of Molecular Biology · doi:10.1016/s0022-2836(64)80115-7 · Cited by 1,809
There's plenty of room at the bottom
Feynman, R. P. (1999) · California Institute of Technology eBooks · doi:10.1201/b10107-3 · Cited by 1,444
Characterization of a human B lymphocyte-specific antigen.
Stashenko, P., Nadler, L. M., Hardy, R., & Schlossman, S. F. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.4.1678 · Cited by 1,076
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture
Fox, M. E., Szoka, F. C., & Fréchet, J. M. J. (2009) · Accounts of Chemical Research · doi:10.1021/ar900035f · Cited by 748
Self-citationGOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 627
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
The Carrier Potential of Liposomes in Biology and Medicine: (First of Two Parts)
Gregoriadis, G. (1976) · New England Journal of Medicine · doi:10.1056/nejm197609232951305 · Cited by 595
Production of functional chimaeric mouse/human antibody
Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984) · Nature · doi:10.1038/312643a0 · Cited by 550
Electronic Properties of Semiconductor Nanowires
Voon, L. C. L. Y., Zhang, Y., Lassen, B., Willatzen, M., Xiong, Q., & Eklund, P. C. (2008) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2008.n03 · Cited by 533
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Szoka, F., Olson, F., Heath, T., Vail, W., Mayhew, E., & Papahadjopoulos, D. (1980) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(80)90558-1 · Cited by 474
Self-citationCancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature
Venditto, V. J., & Simanek, E. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900243b · Cited by 452
Self-citationThere’s Plenty of Room at the Bottom
Feynman, R. (2018) · Feynman and Computation · doi:10.1201/9780429500459-7 · Cited by 420
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
Griffin, J. D., Linch, D., Sabbath, K., Larcom, P., & Schlossman, S. F. (1984) · Leukemia Research · doi:10.1016/0145-2126(84)90001-8 · Cited by 403
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Nadler, L. M., Ritz, J., Hardy, R., Pesando, J. M., Schlossman, S. F., & Stashenko, P. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110005 · Cited by 399
Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., & Kirpotin, D. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4007 · Cited by 380
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
Enzyme entrapment in liposomes
Gregoriadis, G., Leathwood, P. D., & Ryman, B. E. (1971) · FEBS Letters · doi:10.1016/0014-5793(71)80109-6 · Cited by 331
The Carrier Potential of Liposomes in Biology and Medicine: (Second of Two Parts)
Gregoriadis, G. (1976) · New England Journal of Medicine · doi:10.1056/nejm197609302951406 · Cited by 321
New Class of Polymers for the Delivery of Macromolecular Therapeutics
Gonzalez, H., Hwang, S. J., & Davis, M. E. (1999) · Bioconjugate Chemistry · doi:10.1021/bc990072j · Cited by 312
Antibody-Based Immunotherapy of Cancer
Weiner, L. M., Murray, J. C., & Shuptrine, C. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.034 · Cited by 284
Nanomedicine in cancer therapy: Innovative trends and prospects
Blanco, E., Hsiao, A., Mann, A. P., Landry, M. G., Meric‐Bernstam, F., & Ferrari, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01941.x · Cited by 265
New Aspects of Nanopharmaceutical Delivery Systems
Marcato, P. D., & Durán, N. (2008) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2008.274 · Cited by 241
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Trouet, A., Masquelier, M., Baurain, R., & Deprez-De Campeneere, D. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.2.626 · Cited by 233
(1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb68027.x · Cited by 215
Synthesis of Linear, β-Cyclodextrin-Based Polymers and Their Camptothecin Conjugates
Cheng, J., Khin, K. T., Jensen, G. S., Liu, A., & Davis, M. E. (2003) · Bioconjugate Chemistry · doi:10.1021/bc0340924 · Cited by 203
Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin
Davis, M. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.005 · Cited by 171
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates
Cheng, J., Khin, K. T., & Davis, M. E. (2004) · Molecular Pharmaceutics · doi:10.1021/mp049966y · Cited by 123
Preparation, characterization and properties in vitro and in vivo of a paclitaxel–albumin conjugate
Dosio, F., Brusa, P., Crosasso, P., Arpicco, S., & Cattel, L. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)01656-8 · Cited by 116
Yurkovetskiy, A., & Fram, R. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.01.007 · Cited by 100
The Paradox of Peer Review: Admitting too Much or Allowing too Little?
EISENHART, M. A. (2002) · Research in Science Education · doi:10.1023/a:1016082229411 · Cited by 97
Peer-review in a world with rational scientists: Toward selection of the average
Stefan Thurner, A., & Hanel, R. (2011) · The European Physical Journal B · doi:10.1140/epjb/e2011-20545-7 · Cited by 91
Invitro and invivo studies with adriamycin liposomes
Forssen, E. A., & Tökés, Z. A. (1979) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(79)91207-5 · Cited by 81
Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11
Sadzuka, Y., Hirotsu, S., & Hirota, S. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00031-7 · Cited by 74
Shared Idiotypes Expressed by Human B-Cell Lymphomas
Miller, R. A., Hart, S., Samoszuk, M. K., Coulter, C., Brown, S. L., Czerwinski, D. K., Kelkenberg, J., Royston, I., & Levy, R. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909283211302 · Cited by 73
Brem, H., & Lawson, H. C. (1999) · Cancer · Cited by 39
Patterns of technological innovation in biotech
McNamee, L. M., & Ledley, F. D. (2012) · Nature Biotechnology · doi:10.1038/nbt.2389 · Cited by 35
Sapra, P., Kraft, P., Mehlig, M., Malaby, J., Zhao, H., Greenberger, L. M., & Horak, I. D. (2009) · Haematologica · doi:10.3324/haematol.2009.008276 · Cited by 26
Transport d'agents cytostatiques par les protéines plasmatiques
Magnenat, G., Schindler, R., & Isliker, H. (1969) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(69)90086-3 · Cited by 14
Short Asthmatic Children and Human Growth Hormone
Collipp, P. J., & Snyder, R. D. (1968) · Clinical Pediatrics · doi:10.1177/000992286800701106 · Cited by 6
Cited by
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Metadata
- Authors
- Venditto, V. J., & Szoka, F. C.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 65
- Issue
- 1
- Pages
- 80-88
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W1978094989
- Cited by
- 537
- References
- 51
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.